Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin Vascular Effects in CAD
NCT01979614Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Primary completion
- Aug 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of serelaxin in coronary artery disease (CAD), sponsored by Novartis. Started Feb 2014; status: completed.
02
Drugs
serelaxin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01979614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01979614.